Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With 30 years of experience, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services range from standalone process development projects to full development and manufacturing programs through commercialization.
Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals, Inc., has entered a biomanufacturing contract to supply clinical material to Affitech A/S over the next year.
Avid Bioservices, Inc. and Boehringer Ingelheim have entered into a global strategic production alliance agreement, under which Avid will become an approved member of BI's global Production Alliance Network (PAN) Biologics.